General Information of Drug (ID: DM1C0K4)

Drug Name
SDZ-GLC-756 Drug Info
Synonyms GLC-756; SDZ GLC 756; SCHEMBL14392424; BDBM85047; PDSP1_000850
Indication
Disease Entry ICD 11 Status REF
Glaucoma/ocular hypertension 9C61 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
101061738
TTD Drug ID
DM1C0K4

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D1 receptor (D1R) TTZFYLI DRD1_HUMAN Modulator [2]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Dopamine D1 receptor (D1R) DTT DRD1 5.04 4.626 2.459 1.322
Dopamine D2 receptor (D2R) DTT DRD2 5.345 5.634 5.789 5.901
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Glaucoma/ocular hypertension
ICD Disease Classification 9C61
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D1 receptor (D1R) DTT DRD1 8.99E-01 -0.06 -0.3
Dopamine D2 receptor (D2R) DTT DRD2 2.20E-03 -0.51 -1.35
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008736)
2 SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm. 1996;103(1-2):17-30.